Skip to main content
    J

    Journey Medical Corp (DERM)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $3.70
    -0.63 (-14.55%)

    Market Cap: $122.24M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Journey Medical Corp (DERM) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Journey Medical reported revenue of $61.86M for the fiscal year ended Dec 31, 2025, up 10.2% from the year before. That year, net income was -$11.43M with a net margin of -18.5%, operating cash flow was -$12.44M and free cash flow was -$12.44M. The quarter ended Sep 30, 2026 had revenue of $18.97M and net income of -$1.31M.

    Revenue and Margins

    The operating margin was -13.2% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $22.59M, a compound annual rate of 11.8%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$61.86M+10.2%66.2%-13.2%-18.5%
    Dec 2024$56.13M-29.1%62.8%-24.4%-26.1%
    Dec 2023$79.18M+7.5%71.1%-2.6%-4.9%
    Dec 2022$73.67M+16.7%58.2%-37.4%-40.2%
    Dec 2021$63.13M+41.8%49.2%-55.2%-69.7%
    Dec 2020$44.53M+27.5%67.2%17.6%11.9%
    Dec 2019$34.92M-17.5%69.8%15.1%10.4%
    Dec 2018$42.34M+832.4%97.2%-505.4%-523.3%
    Dec 2017$4.54M-79.9%100.0%-6613.7%-6678.3%
    Dec 2016$22.59MN/A100.0%-401.3%-394.4%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$61.86M$56.13M$79.18M$73.67M$63.13M$44.53M$34.92M$42.34M$4.54M$22.59M
    Cost of revenue$20.92M$20.88M$22.89M$30.77M$32.08M$14.59M$10.53M$1.18MN/AN/A
    Gross profit$40.93M$35.26M$56.29M$42.89M$31.05M$29.94M$24.39M$41.16M$4.54M$22.59M
    Research and development$480.00K$9.86M$7.54M$10.94M$16.56M$0$0$80.55M$104.41M$83.17M
    Operating income-$8.17M-$13.68M-$2.07M-$27.52M-$34.88M$7.85M$5.26M-$213.98M-$300.33M-$90.62M
    Net income-$11.43M-$14.67M-$3.85M-$29.63M-$43.99M$5.28M$3.63M-$221.54M-$303.26M-$89.08M
    EBITDA-$3.45M-$9.97M$1.87M-$23.18M-$30.20M$9.37M$6.44M-$205.54M-$294.78M-$87.42M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$18.97M$18.51M$15.96M$16.08M$17.63M$15.01M$13.14M$13.62M$14.63M$14.86M$13.03M$15.26M
    Gross profit$13.08M$12.37M$9.74M$10.64M$11.88M$10.07M$8.35M$8.94M$10.16M$9.13M$7.03M$13.01M
    Operating income-$530.00K$456.00K-$1.49M-$443.00K-$1.53M-$2.88M-$3.32M$2.23M-$2.89M-$2.93M-$10.09M-$2.10M
    Net income-$1.31M-$312.00K-$2.23M-$1.25M-$2.31M-$3.80M-$4.07M$1.52M-$2.39M-$3.36M-$10.44M-$2.14M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $25.28M exceeded cash and equivalents by $1.19M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$94.59M$80.24M$76.85M$105.16M$97.28M$51.91M$33.86M$344.32M$560.79M$312.60M
    Current assets$66.87M$48.18M$56.45M$77.68M$84.49M$35.24M$25.27M$335.41M$556.61M$283.99M
    Cash and equivalents$24.09M$20.30M$27.44M$32.00M$49.08M$8.25M$4.80M$104.98M$295.92M$41.79M
    Total liabilities$62.74M$60.17M$56.50M$88.18M$55.24M$41.61M$31.11M$353.36M$411.14M$65.23M
    Short-term debt$0$708.00K$3.10M$2.95M$812.00K$4.52M$83.00KN/A$4.63M$3.02M
    Long-term debt$25.28M$24.88M$14.62M$19.83M$0$13.36M$5.22MN/AN/AN/A
    Shareholder equity$31.85M$20.07M$20.35M$16.98M$42.04M$10.29M$2.75M-$9.04M$149.65M$247.37M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$103.85M$98.36M$91.53M$94.59M$85.19M$81.16M$84.96M$80.24M$64.04M$65.19M$66.57M$76.85M
    Total liabilities$71.60M$66.24M$60.70M$62.74M$59.29M$61.91M$63.42M$60.17M$53.12M$53.89M$53.62M$56.50M
    Cash and equivalents$22.32M$25.64M$27.22M$24.09M$24.95M$20.29M$21.07M$20.30M$22.46M$23.91M$24.06M$27.44M
    Shareholder equity$32.25M$32.11M$30.83M$31.85M$25.90M$19.25M$21.54M$20.07M$10.93M$11.29M$12.95M$20.35M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$12.44M-$9.13M$5.24M-$13.53M-$2.18M$5.13M$9.02M-$213.10M-$103.96M-$74.11M
    Capital expenditures$0$15.00M$5.00M$20.00M$0$1.20M$2.40M$616.00K$278.00K$753.00K
    Free cash flow-$12.44M-$24.13M$240.00K-$33.53M-$2.18M$3.93M$6.62M-$213.71M-$104.24M-$74.86M
    Dividends paidN/AN/AN/A$371.00K$1.55MN/AN/AN/AN/AN/A
    Share repurchasesN/AN/AN/A$371.00K$1.55MN/AN/AN/AN/AN/A
    Investing cash flow$0-$15.00M-$5.00M-$20.00M-$10.00M-$1.20M-$2.40M-$13.23M-$104.43M-$130.29M
    Financing cash flow$16.23M$16.99M-$4.80M$16.46M$53.02M-$487.00K-$3.55M$35.38M$462.52M$138.95M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$3.44M-$1.73M$2.91M-$6.28M-$2.38M-$942.00K-$2.83M$2.23M-$1.16M-$5.18M-$5.02M-$16.52M
    Capital expendituresN/AN/A$0$0$0$0$0$0$0$0$0$5.00M
    Free cash flowN/AN/A$2.91M-$6.28M-$2.38M-$942.00K-$2.83M$2.23M-$1.16M-$5.18M-$5.02M-$21.52M
    Last 12 quarters

    Frequently Asked Questions About DERM

    What is Journey Medical's annual revenue?

    Journey Medical reported revenue of $61.86M for the fiscal year ended Dec 31, 2025.

    How fast is Journey Medical's revenue growing?

    Revenue was up 10.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -5.7%.

    Is Journey Medical profitable?

    No. Journey Medical reported net income of -$11.43M for the fiscal year ended Dec 31, 2025, with a net margin of -18.5%.

    How much free cash flow does DERM generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$12.44M minus capital expenditures of $0 produced free cash flow of -$12.44M.

    How much debt does Journey Medical have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $25.28M, short-term debt of $0 and cash and equivalents of $24.09M.